NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

World Disease Weekly


Recent studies from University of California add new data to HIV/AIDS clinical trial



*
World Disease Weekly Library
Library Home

This article was published in World Disease Weekly, which you can subscribe to online.

NewsRx
NewsRx
2009 JUL 28 - (NewsRx.com) -- A report, 'The Oral HIV/AIDS Research Alliance: updated case definitions of oral disease endpoints,' is newly published data in Journal of Oral Pathology & Medicine. According to recent research from the United States, "The Oral HIV/AIDS Research Alliance (OHARA) is part of the AIDS Clinical Trials Group (ACTG), the largest HIV clinical trials organization in the world. Its main objective is to investigate oral complications associated with HIV/AIDS as the epidemic is evolving, in particular, the effects of antiretrovirals on oral mucosal lesion development and associated fungal and viral pathogens."

"The OHARA infrastructure comprises: the Epidemiologic Research Unit (at the University of California San Francisco), the Medical Mycology Unit (at Case Western Reserve University) and the Virology/Specimen Banking Unit (at the University of North Carolina). The team includes dentists, physicians, virologists, mycologists, immunologists, epidemiologists and statisticians. Observational studies and clinical trials are being implemented at ACTG-affiliated sites in the US and resource-poor countries. Many studies have shared end-points, which include oral diseases known to be associated with HIV/AIDS measured by trained and calibrated ACTG study nurses. In preparation for future protocols, we have updated existing diagnostic criteria of the oral manifestations of HIV published in 1992 and 1993. The proposed case definitions are designed to be used in large-scale epidemiologic studies and clinical trials, in both US and resource-poor settings, where diagnoses may be made by non-dental healthcare providers," wrote C.H. Shiboski and colleagues, University of California.

The researchers concluded: "The objective of this article is to present updated case definitions for HIV-related oral diseases that will be used to measure standardized clinical end-points in OHARA studies, and that can be used by any investigator outside of OHARA/ACTG conducting clinical research that pertains to these end-points."

Shiboski and colleagues published their study in the Journal of Oral Pathology & Medicine (The Oral HIV/AIDS Research Alliance: updated case definitions of oral disease endpoints. Journal of Oral Pathology & Medicine, 2009;38(6):481-8).

For additional information, contact C.H. Shiboski, University of California San Francisco, Dept. of Orofacial Sciences, School of Dentistry, San Francisco, CA 94143-0422 USA..

Publisher contact information for the Journal of Oral Pathology & Medicine is: Blackwell Publishing Inc., 350 Main St., Malden, MA 02148, USA.

Keywords: United States, San Francisco, HIV/AIDS Clinical Trial, AIDS, Acquired Immunodeficiency Syndrome, Antivirals, Clinical Trial Research, Epidemics, HIV, Human Immunodeficiency Virus, Oral Pathology, Virology.

This article was prepared by World Disease Weekly editors from staff and other reports. Copyright 2009, World Disease Weekly via NewsRx.com.

NewsRx Passes
Advertisement
------------------------
Security by Verisign PR Login